EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors

Serge A.L. Zander(The Netherlands Cancer Institute), Sven Rottenberg(University of Bern), Wendy Sol(The Netherlands Cancer Institute), Lee M. Greenberger(Enzon Pharmaceuticals (United States)), Yixian Zhang(Fujian Medical University), Piet Borst(The Netherlands Cancer Institute), Jos Jonkers(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society)
PLoS ONE
September 17, 2012
10.1371/journal.pone.0045248
Cited by 32

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
|Nature Structural & Molecular Biology|2010|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884